Pedro Barata is joined by Brian Shuch to discuss his investigator-initiated phase 2 trial evaluating girentuximab PET-CT imaging for detecting residual disease after nephrectomy in clear cell renal ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Zachary Klaassen speaks with Jie Luo about his Prostate Cancer Foundation Young Investigator Award work on androgen receptor enhanceosomes in prostate cancer. Dr. Luo explains that enhanceosomes are ...

Zachary Klaassen is joined by Rahul Aggarwal to discuss final results from the PRESTO trial evaluating treatment intensification for high-risk biochemically recurrent prostate cancer. The trial ...

Andrea Necchi presents GDFATHER-NEO trial results, evaluating neoadjuvant nivolumab plus visugromab versus nivolumab-placebo in 31 cisplatin-ineligible/refusing muscle-invasive bladder cancer patients ...

Is Primary Retroperitoneal Lymph Node Dissection the Way Forward for Patients with Testicular Seminoma and Limited Retroperitoneal Metastases? - Beyond the Abstract ...

Rashid Sayyid and Zachary Klaassen discuss the 2024 updates to the NCCN guidelines for metastatic castration-resistant prostate cancer (mCRPC) treatment. They review the current management algorithm, ...

In this discussion, Matthew Cooperberg, MD, speaks with Monique Roobol, PhD, lead author of the NEJM publication “European Study of Prostate Cancer Screening - 23-Year Follow-up.” Dr. Roobol reviews ...

Oliver Sartor: Hi, I'm Oliver Sartor with Uro Today, covering metastatic castration resistant prostate cancer at ASCO 2025. A real delight for me to welcome Mark Stein, associate professor at Columbia ...

Diane Newman discusses with Kristine Talley their ongoing implementation study examining the Incontinence Helping Others Manage at Home telephone counseling program for older Medicaid recipients. The ...

(UroToday.com) In this presentation, Dr. Chi presented the results of the MAGNITUDE study. MAGNITUDE is a randomized phase 3 study of abiraterone acetate and prednisone (AAP) plus niraparib (NIRA) or ...

Read the Full Video Transcript Alicia Morgans: Hi. I'm so excited to be here at ASCO GU 2024, where I am speaking with Dr. Alan Bryce, who is the Chief Clinical Officer of City of Hope, Arizona, which ...